Skip to NavigationSkip to content

Cancer Drugs Fund

Pfizer's Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) to be made available via the Cancer Drugs Fund as a treatment for advanced breast cancer.

Specifically, the ruling relates to patients whose tumours are hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, and who have already received endocrine therapy.

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to be made available via the Cancer Drugs Fund.

It will be used for the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, who have received prior endocrine therapy.

NICE rejects Keytruda for routine use in NHS bladder cancer treatment

The National Institute for Health and Care Excellence (NICE) has given an initial ‘no’ for Keytruda’s (pembrolizumab) use in treating bladder cancer through the NHS.

The immunotherapy is currently available as a treatment option on the NHS through the Cancer Drugs Fund, and will continue to be until at least January 2020 when NICE will review its initial decision.

AstraZeneca's Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers

NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adult BRCA+ patients that have responded to first-line platinum-based chemotherapy.

The medicine will be made available via the Cancer Drugs Fund while additional data is harvested from an ongoing clinical trial. It was previously approved by the UK watchdog, but not until much later in the treatment pathway, in advanced ovarian cancer.

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to patients in England via the Cancer Drugs Fund (CDF) for the first-line treatment of untreated renal cell carcinoma (RCC), the most common form of kidney cancer.

The drug’s immediate availability through this new pathway provides RCC with another treatment option, which is particularly meaningful as current NHS standard of treatment such as pazopanib, sunitinib, tivozanib or cabozantinib are associated with side-effects including hand and

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer Drugs Fund as a treatment option for melanoma, NICE has revealed, in a U-turn on a ruling made earlier this year.

Specifically, Opdivo will be reimbursed to patients with stage 3 and 4 melanoma who have lymph node involvement and who have previously undergone surgery – a group of eligible patients which NICE estimates numbers around 1,480.

Cancer Drugs Fund to offer MSD's Keytruda for lung cancer

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces it has agreed to recommend the drug in treatment-naive non-small-cell lung cancer, whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

The submission of evidence to support the drug’s benefits drove the decision, showing that Keytruda improvised progression-free survival by around four months compared to standard of care pemetrexed with platinum chemotherapy, allowing NICE to determine that

Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) for patients under the age of 25 via the Cancer Drugs Fund.

Eligible patients within this age range will have proven unresponsive to current treatment – blinatumomab or chemotherapy – or relapsed following stem cell transplant, so it has been estimated that around 25 to 30 people will benefit from the decision in England each year.

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for inclusion in the Cancer Drugs Fund (CDF) for the treatment of squamous cell carcinoma of the head and neck which has metastasized in patients who have not responded to chemotherapy within six months.

NICE gives final draft guidance on two key cancer drugs

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the treatment of gastrointestinal stromal tumours (GIST), and Roche’s Erivedge (vismodegib) in the treatment of advanced basal cell carcinoma (BCC) that cannot be treated with surgery or radiotherapy.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches